TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stepped Care for Depression and Musculoskeletal Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate or severe pain in the back, hips, or knees for at least 3 months prior to study entry~* History of or current use of at least one medication for pain~* English-speaking~Exclusion Criteria:~* Moderate to severe cognitive impairment~* Schizophrenia or other psychotic disorders~* Receiving disability benefits for pain~* Anticipated life expectancy less than 12 months~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stepped Care (Type: EXPERIMENTAL): Stepped care group
- Usual Care (Type: ACTIVE_COMPARATOR): Treatment as usual group
- No Treatment (Type: NO_INTERVENTION): Participants without depression group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~* Males or non-pregnant, non-lactating females~* Body Mass Index (BMI) between 18.5 - 32.0, inclusive.~* Suitable veins for cannulation~Exclusion Criteria:~* Employee of site or the sponsor~* Any disease that poses an unacceptable risk to participants~* Abnormal ECG~* Abnormal labs~* Abnormal vital signs~* Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological disorder~* Positive serology for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) type 1~* Current smokers or history of smoking within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- VNRX-5133 (Type: EXPERIMENTAL): IV infusion
- Placebo (Type: PLACEBO_COMPARATOR): IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~AML project~* inclusion in studies of the DSIL or OSHO group for AML~* AML M3/M3v can be included only when in complete remission~* age 16 - 80 years~* written informed consent~Autologous project~* AMl and ALL patients in first or second remission~* low grade or high grade non hodgkin lymphoma or morbus hodgkin or multiple myeloma~* conditioning regime: TBI 8-12 Gy/Cy 120 or BEAM or BU/CY or Melphalan 140-200mg/m2 or a similarly intensive chemotherapy regime~* age 16 - 65 years~Exclusion Criteria:~AML project~* known refractoriness to platelet transfusion~* known major bleeding with thrombocytopenia when the reason for bleeding is still ongoing~* known plasmatic coagulation disorder~* patient unable to give informed consent~Autologous project~* known refractoriness to platelet transfusion~* known major bleeding with thrombocytopenia when the reason for bleeding is still ongoing~* known plasmatic coagulation disorder~* patient unable to give informed consent~* patients with pulmonal or cerebral lesions due to infection or neoplasm~* patients with al-amyloidosis

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
- 2 (Type: ACTIVE_COMPARATOR): In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IV Haloperidol for the Treatment of Headache in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Emergency Department patients that complain of headache or migraine~* Males and females age 13-55~* English is primary language~Exclusion Criteria:~* Abnormal blood pressure (\>200/100)~* Sudden rapid onsent (normal to worst pain in minutes)~* Fever~* Trauma~* Any history of masses, strokes, head injury or other causes of abnormal anatomy~* QT greater than 450 ms on EKG~* Allergy to Haldon~* Any altered mental status (GCS \<15)~* Pregnancy~* Any abnormalities on neurologic exam~* Any clinician concern that would require CT scan of brain~* Any prisoner or ward of state

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Haloperidol (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole in Children and Adolescents With Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Child and adolescent patients with bipolar I disorder, manic or mixed episode with or without psychotic features~Exclusion Criteria:~* Patients with certain other psychological disorders~* Patients with a co-morbid serious, uncontrolled systemic illness~* Patients with significant risk of committing suicide

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Aripiprazole 10 mg tablet
- 2 (Type: ACTIVE_COMPARATOR): Aripiprazole 30 mg tablet
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Anticholinesterase Drugs on Sleep in Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer's disease based on the probability criteria of the Alzheimer's Disease and Related Disorders Association~* Rated 1 and 2 (mild to moderate level) on the Brazilian version of the Clinical Dementia Rating~Exclusion Criteria:~* Other causes of dementia~* Other severe medical or psychiatric disease~* Clinical indication of psychoactive drugs other than experimental drug

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Donepezil treated Alzheimer patients
- B (Type: PLACEBO_COMPARATOR): Placebo treated Alzheimer patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of non-childbearing potential~* Pain present for more than 3 months after healing of herpes zoster skin rash~* VAS score of \>=40mm at screening and baseline visits~Exclusion Criteria:~* Patients with pain conditions which might impair the assessment of postherpetic neuralgia~* Skin conditions in the affected dermatome that could alter sensation other than postherpetic neuralgia~* History or diagnosis of DSM IV major depressive disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Number of Patients Who Reach Optimal Cholesterol Levels on Each of Three Different Treatments (0653A-121)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient Is Male Or Female And Aged Over 18~* Patient Provides Written Informed Consent~* Patient Has A Fasting Ldl-C Level \>2mmol/L At Both Visit 1 And Again At Visit 2~* Patient Has Established Cvd, Diabetes Or At High Risk Of Cvd (\>20 % Risk Over 10 Years, Framingham Scale)~* Patient Has Taken Simvastatin 40mg Continuously For The Past 6 Weeks~* Patient Has A Fasting Triglyceride Level Of \<3.7mmol/L~* Patient Has Hba1c \<9% At Visit 1~* Patient Is 75% Compliant With Medication Between Visit 1 And Visit 2~Exclusion Criteria:~* Patient Is Hypersensitive To Any Of The Study Medications Or Their Components~* Patient Has A History Of, Or Active Liver Disease (Persistent Elevation Of Alt / Ast (\>3xuln)~* Patient Is Pregnant, Lactating, Or A Female Patient Of Childbearing Potential Not Using Adequate Contraception~* Patient Has Severe Renal Impairment: Creatinine Clearance \<30ml/Min (Cockcroft-Gault Equation) (In Patients With Moderate Renal Impairment: \<60ml/Min, The Dose Of Rosuvastatin Will Be 5mg In Line With The Spc)~* Patient Has Uncontrolled Endocrine Or Metabolic Disease Known To Influence Serum Lipids Or Lipoproteins (I.E. Secondary Causes Of Hyperlipidaemia Such As Hypothyroidism Or Hyperthyroidism)~* Patient Has A Recent History Of, Or Current, Alcohol Abuse~* Patient Has Ck \>10 X Uln At Visit 1 Or Visit 2~* Patient Has Fasting Ldl-C \>4.2mmol/L~* Patient Has Any Acute Or Serious Condition, Or History Suggestive Of Myopathy Or Predisposing To The Development Of Renal Failure Secondary To Rhabdomyolysis (E.G. Sepsis, Hypotension, Major Surgery, Trauma, Severe Metabolic, Severe Endocrine And Electrolyte Disorders Or Uncontrolled Seizures)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: Drug
- 2 (Type: ACTIVE_COMPARATOR): Arm 2: Active comparator
- 3 (Type: ACTIVE_COMPARATOR): Arm 3: Active comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* History of PONV and/or motion sickness.~* Have not smoked for the last 6 months.~* Having certain types of abdominal, breast or shoulder surgeries.~Exclusion criteria:~* Pregnant or breastfeeding.~* Taking certain medications.~* Have certain pre-existing medical conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Derived Stem Cell Transplantation in T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients with type 2 diabetes mellitus between 30 and 70 years of age.~* Failure to triple oral hypoglycemic agent and on stable doses of insulin for at least 3 months.~* On vildagliptin,pioglitazone and metformin for at least 3 months along with Insulin to maintain euglycemia.~* HbA1c \< 7.5%.~* Insulin requirement ≥0.4 IU/kg/d.~* GAD antibody negative status.~Exclusion Criteria:~* Patients with type 1 diabetes mellitus or secondary diabetes.~* Patients with serum creatinine \> 1.5 mg/dl.~* Abnormal liver function tests (defined as value of transaminases \> 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).~* History of cholecystitis/ cholelithiasis/ cholecystectomy~* Seropositivity for HIV, HBsAg and hepatitis C virus (HCV).~* History of myocardial infarction or unstable angina in the previous 3 months.~* History of malignancy~* Patients with active infections.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- mesenchymal stem cell transplantation (Type: EXPERIMENTAL): Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.
- Control (Type: SHAM_COMPARATOR): vildagliptin+metformin+pioglitazone and on Insulin \>0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
- MNC's TRANSPLANTATION (Type: EXPERIMENTAL): Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of \>0.4unit/Kg for blood glucose control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Volunteer to participate in this clinical study; Completely understand and know this study as well as sign the informed consent form (ICF);~2. Age ≥ 18 years and ≤ 80 years when ICF is signed;~3. Histologically confirmed invasive breast carcinoma with a primary tumor size of more than (\>) 2 centimeters (cm) by standard local assessment technique; Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4, any N, M0); HER2-positive breast cancer confirmed by immunohistochemistry or HER2 gene amplification by in situ hybridization; Estrogen receptor and Progesterone receptor negative.~4. Eastern Cooperative Oncology Group Performance Status equal to or less than (\<=) 1.~5. Baseline left ventricular ejection fracture \>= 55% measured by echocardiography (preferred) or multiple gated acquisition scan~Exclusion Criteria:~1. Stage IV metastatic breast cancer;~2. Inflammatory breast cancer;~3. Previous anti-cancer therapy or radiotherapy for any malignancy;~4. History of malignancies other than colorectal cancer within 5 years prior to randomization, excluding cutaneous basal cell carcinoma, cervical carcinoma in situ, and thyroid papillary adenocarcinoma of non-melanoma after radical treatment;~5. Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy;~6. Major surgical procedure within 4 weeks prior to randomization or from which the participant has not fully recovered;~7. Serious cardiac illness or medical condition;~8. Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness;~9. Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol;~10. Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Plus（+） QL1209 + Docetaxel (Type: EXPERIMENTAL): Prior to surgery: trastuzumab, QL1209, and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: QL1209 Drug: Trastuzumab Procedure: Surgery
- Trastuzumab Plus（+） Pertuzumab + Docetaxel (Type: ACTIVE_COMPARATOR): Prior to surgery: trastuzumab,pertuzumab , and docetaxel for 4 cycles (1 cycle = 21 days) Drug: Docetaxel Drug: Pertuzumab Drug: Trastuzumab Procedure: Surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis os asthma, taking 200-1000mcg budesonide or equivalent per day~* FENO greater than 30ppb on treatment~Exclusion Criteria:~* Recent RTI or prednisolone~* Smoking within 1 year or 10 pack years~* ABPA, COPD, bronchiectasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High dose ICS (Type: ACTIVE_COMPARATOR): Fluticasone Propionate 250mcg bid
- Low dose ICS (Type: ACTIVE_COMPARATOR): Fluticasone propionate 50mcg bid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must be between the ages of 18 and 80, inclusive~* Subject must have a diagnosis of prosthetic joint infection (PJI) in a hip or knee joint which has never previously been totally revised because of an infection and for which they are anticipated to undergo a two-stage replacement surgery~* Subject must have a positive microbiological identifier of staphylococci.~* If Subject is female of childbearing potential, must be willing to practice reliable birth control~Exclusion Criteria:~* Subject has permanent intravascular prosthetic material such as heart valves or pacemakers~* Subject has a creatinine clearance (CLCR) \<30 mL/min as determined by the Cockcroft-Gault equation using actual body weight.~* Subject has significant hepatic dysfunction~* Subject has a fungal or mycobacterial PJI~* Subject is known to be HIV-infected with CD4 count ≤ 200 cells/ mm3~* Subject has an abnormal creatine phosphokinase (CPK) (elevated CPK level ≥ 2x ULN) at baseline as measured by central laboratory~* Subject is currently under treatment with chemotherapeutic agents excluding chronic maintenance therapy (e.g. tamoxifen to prevent relapse of primary breast cancer)~* Subject is pregnant, nursing, or lactating.~* Subject is receiving or is expected to receive chronic immunosuppressive therapy during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Daptomycin 6 mg/kg (Type: EXPERIMENTAL): Daptomycin (6 mg/kg every 24 hours \[q24h\]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
- Daptomycin 8 mg/kg (Type: EXPERIMENTAL): Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
- Comparator (Type: ACTIVE_COMPARATOR): Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete